Clinical trials: Empagliflozin
Post-operative Atrial Fibrillation, CABG
Empagliflozin to Prevent Post-Operative Atrial Fibrillation
This is an interventional, double-blind, placebo controlled, multicenter, randomized clinical trial with allocation sequence concealment and blinded endpoint adjudication.
- Trial name
- EMPOAF (NCT06124937)
- Testing
- Empagliflozin 10 MG
- Where
- 2 sites in Iran
- Volunteers
- 492 people
- Sponsor
- Rajaie Cardiovascular Medical and Research Center
Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
Effect of SGLT2 Inhibitors on NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy
To rule out the beneficial effect of SGLT2-I to reduce liver fat, and change in inflammatory markers (ALT, AST) in type 2 diabetic patients with non-alcoholic fatty liver disease.
- Trial name
- NCT06668753
- Testing
- Dapagliflozin 10mg Tab or Empagliflozin 10 mg Tab
- Volunteers
- 114 people
- Sponsor
- Assiut University
Diabetes Mellitus, Type 2
A Study to Observe the Effectiveness of Empagliflozin, Other SGLT-2 Inhibitors, or DPP-4 Inhibitors in Patients With Type 2 Diabetes
Non-interventional, multi-country cohort study using existing data and including adults (≥18 years) with a diagnosis of Type 2 diabetes mellitus.
- Trial name
- NCT03817463
- Testing
- Subjects treated with Empagliflozin or any Sodium-glucose cotransporter-2 (SGLT-2) inhibitor, Subjects treated with Dipeptidyl peptidase-4 (DPP-4) inhibitor
- Where
- 13 sites in Denmark, Finland and 9 more
- Volunteers
- 327,624 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Doses of BI 10773 Tablets
To investigate safety, tolerability, pharmacokinetics and pharmacodynamics of BI 10773 with repeat dosing for eight days and the exploration of the pharmacokinetics and pharmacodynamics of BI 10773 after multiple dosing…
- Trial name
- NCT01924767
- Testing
- BI 10773
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Comparative Effectiveness of Empagliflozin in the US
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014.
- Trial name
- NCT03363464
- Testing
- Empagliflozin, DPP-4 inhibitor, GLP-1 receptor agonist
- Where
- United States
- Volunteers
- 230,000 people
- Sponsor
- Boehringer Ingelheim
SGLT2i Kideny Protection Against Contrast in Diabetic Kidney
SGLT2 Inhibitors Prophylaxis Against Post-contrast Acute Kidney Injury in Diabetic Kidney Disease?
We will look for the possible effect of SGLT2i as a single agent to prevent post-contrast Acute Kidney Injury in diabetic kidney disease.
- Trial name
- NCT04853615
- Testing
- Empagliflozin 25 MG
- Volunteers
- 800 people
- Sponsor
- Fayoum University
Healthy
This Study in Healthy People Tests Whether Taking a Low Strength of Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills
The primary objective of this trial is to establish the bioequivalence of two empagliflozin/linagliptin/metformin extended release (XR) fixed dose combination (FDC) tablets (Test, T) compared with the same doses of the individual…
- Trial name
- NCT03629054
- Testing
- Empagliflozin, Metformin HCl, Linagliptin (fixed dose combination), Empagliflozin, Linagliptin
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Glomerulonephritis, Immunoglobulin A Nephropathy
Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.
Idiopathic immunoglobulin A nephropathy (IgAN) is the most common biopsy-proven glomerulonephritis in the world. Approximately 40% of IgAN patients reach end-stage kidney disease (ESKD) 20 years after their kidney biopsy.
- Trial name
- CLIgAN (NCT04662723)
- Testing
- Corticosteroid, Renin-angiotensin sytem blockers, Sodium-glucose cotransporter 2 inhibitor
- Where
- 2 sites in Italy
- Volunteers
- 878 people
- Sponsor
- Fondazione Schena
Acute Decompensated Heart Failure
Empagliflozin and Dapagliflozin in Patients Hospitalized for Acute Decompensated Heart Failure
National, multicenter, randomized, double-blind, parallel-group, stratified by SGLT-2 inhibitor type, placebo-controlled trial, - a Phase III study.
- Trial name
- EMPATHY (NCT05776043)
- Testing
- Empagliflozin 10 MG, Dapagliflozin 10 MG
- Where
- Poland
- Volunteers
- 1,364 people
- Sponsor
- Medical University of Warsaw
Hypertension, Type II Diabetes
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Objectives: Primary 1. Primary prevention of new onset of hypertension Secondary 1. Reduction of 24h BP in type II diabetics with prehypertension 2.
- Trial name
- PREHYPD (NCT01001962)
- Testing
- empagliflozin, Metformin
- Where
- Greece
- Volunteers
- 1,054 people
- Sponsor
- Aristotle University Of Thessaloniki
Pancreatitis, Chronic, Pancreatitis, Acute
Pioglitazone Versus Empagliflozin for Chronic Pancreatitis/Recurrent Acute Pancreatitis/Acute Pancreatitis Associated Diabetes Mellitus
The purpose of this study is to evaluate efficacy of pioglitazone (PIO) versus empagliflozin (EMPA) to improve glycemic control in people with Chronic Pancreatitis (CP) or Recurrent Acute Pancreatitis (RAP) or Acute Pancreatitis…
- Conditions
- Pancreatitis, Chronic, Pancreatitis, Acute, Diabetes Mellitus
- Trial name
- PEP-DM (NCT06729996)
- Testing
- Pioglitazone (PIO), Empagliflozin (EMPA)
- Where
- 3 sites in United States
- Volunteers
- 50 people
- Sponsor
- Mayo Clinic
Heart Failure
Jardiance® Post Marketing Surveillance (PMS) in Korean Patients With Chronic Heart Failure
The primary objective of this study is to monitor the safety profile of Jardiance® in Korean patient with chronic heart failure (New York Heart Association (NYHA) class II-IV) in a routine clinical setting.
- Trial name
- NCT05236673
- Testing
- JARDIANCE®
- Where
- 21 sites in South Korea
- Volunteers
- 676 people
- Sponsor
- Boehringer Ingelheim
Fatty Liver, Nonalcoholic, Diabetes Mellitus, Type 2
Anti-diabetic Drugs and Fatty Liver Management
Type 2 DM is one of the major risk factors for development of non-alcoholic fatty liver disease. The pooled prevalence of fatty liver among diabetics is 54% (95% CI 45%-64%).
- Trial name
- NCT05041673
- Testing
- Metformin
- Where
- Egypt
- Volunteers
- 120 people
- Sponsor
- Alexandria University
Heart Failure
Emp-Activity: Empagliflozin Functional Capacity
This is a multinational non-interventional study based on newly collected data to assess demographics, disease, and treatment pattern of patients with chronic Heart Failure (HF) in a two-cohort design: one cohort will receive…
- Trial name
- NCT05350202
- Testing
- Empagliflozin
- Where
- 350 sites in Bulgaria, Czechia and 4 more
- Volunteers
- 3,431 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2 DM
Glycemic Control With Triple Pathway Approach Through Empagliflozin, Linagliptin and Metformin Combination
The efficacy and safety of a triple-pill combination therapy for advanced type 2 diabetes care. The study aims to assess the impact of 3 Oral Anti Diabetic (OAD) drugs on metabolic control, patient compliance, weight management…
- Trial name
- GLYCO-3P (NCT06862739)
- Testing
- Empagliflozin+Linagliptin+Metformin
- Where
- 2 sites in Pakistan
- Volunteers
- 800 people
- Sponsor
- Nabiqasim Industries (Pvt) Ltd
Acute Kidney Injury
The Efficacy and Safety of Sodium-glucose Cotransporter 2 Inhibitors in Patients With Acute Kidney Disease
Acute kidney disease (AKD) happens between 7 and 90 days after an initial kidney injury (AKI). This period is crucial because it can determine whether the condition worsens into chronic kidney disease (CKD).
- Trial name
- ESS-AKD (NCT06528405)
- Testing
- dapagliflozin, Other anti-diabetic drug or no anti-diabetic drug, empagliflozin
- Where
- Taiwan
- Volunteers
- 264 people
- Sponsor
- National Taiwan University Hospital
Anemia in CKD Patients
Effect of SGLT2 Inhibitors on Anemic CKD Patients
anemia is a common complication of CKD patients and affect the quality of life and increase morbidity and mortality. managing anemia in CKD patients remains challenging conventional therapy including iron and ESAs which has its…
- Trial name
- NCT07334145
- Testing
- SGLT2 inhibitor
- Where
- Egypt
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sohag University
Pulmonary Arterial Hypertension
Empagliflozin to Improve Right Ventricular Function in Pulmonary Arterial Hypertension
Randomized, triple-masked, parallel arm clinical trial of empagliflozin versus placebo in pulmonary arterial hypertension (PAH) participants on stable approved PAH-targeted medical therapy.
- Trial name
- EmPATH (NCT06992440)
- Testing
- Empagliflozin 10 MG
- Where
- 3 sites in United States
- Volunteers
- 78 people
- Sponsor
- Gustavo A Heresi, MD, MS
Healthy
This Study Tests Whether Taking the Medicines Empagliflozin, Linagliptin, and Metformin Together in 1 Pill is the Same as Taking Them in Separate Pills. The Study is Done in Healthy Men and Women and Measures the Amount of Each Medicine in the Blood
To establish the bioequivalence of one fixed dose combination (FDC) tablet of empagliflozin/linagliptin/metformin extended release (XR) versus the free combination of empagliflozin tablet, linagliptin tablet, and metformin XR…
- Trial name
- NCT03259490
- Testing
- Empagliflozin/linagliptin/metformin HCl, Empagliflozin, Linagliptin
- Where
- Germany
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
Bioavailability of a Fixed Dose Combination Tablet With Empagliflozin (BI 10773) and Metformin Compared With the Monocomponents and Effect of Food on Bioavailability
The objective of the current study is to determine the relative bioavailability of a BI 10773 / metformin fixed dose combination tablet compared to single tablets of BI 10773 and metformin when administered together and to assess…
- Trial name
- NCT01211197
- Testing
- C: BI 10773 / metformin tablet, B: BI 10773 tablet and metformin tablet, A: BI 10773 / metformin tablet
- Where
- Germany
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim